One sample, a lifetime of insight: How GenomicMD is redefining preventive care

GenomicMD is on a mission to make precision medicine truly precise.

GenomicMD is on a mission to make precision medicine truly precise — moving beyond outdated family history surveys to deliver clinical-grade genomic risk assessments that give patients and physicians a clear, actionable picture of lifetime disease risk. In the latest episode of What's Next: Stories of Industry Reinvention by TechNexus Venture Collaborative , GenomicMD founder Jason Lobel speaks with TechNexus Director of Communications Jim Dallke on how GenomicMD's Polygenic Risk Score (PRS) panels work, why traditional risk screening falls short, and how their technology identifies two to ten times more at-risk patients than conventional methods. Lobel explains how analyzing thousands of genetic variants — rather than a single gene — produces a far more accurate risk profile for conditions like cardiovascular disease, cancer, diabetes, and more. A defining milestone: Endeavor Health became the first hospital system in the world to adopt GenomicMD's approach, bringing a decade of translational research into real clinical practice. With one sample delivering a lifetime of insight, GenomicMD is helping healthcare shift from reactive treatment to proactive prevention — and building a defensible position at the intersection of genomics, enterprise healthcare, and Chicago's rich ecosystem of payers and medical institutions. Dive into the full interview below:

By Jim Dallke at TechNexus Venture Collaborative